SEEL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 11:46):

Stats
Today's Volume	192 789
Average Volume	439 059
Market Cap	4.51M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-1.480 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00400 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-29	Golembiewski Michael Joseph	Buy	417	Common Stock
2024-01-12	Mehra Raj	Buy	70 383	Stock Option (right to buy)
2024-01-12	Golembiewski Michael Joseph	Buy	24 537	Stock Option (right to buy)
2024-01-04	Pascoe Richard W	Buy	1 666	Stock Option (right to buy)
2024-01-04	Dalesandro Margaret	Buy	1 666	Stock Option (right to buy)

INSIDER POWER
100.00
Last 92 transactions
Buy: 14 639 227 \| Sell: 4 987 490

Volume Correlation

Long: 0.37 (neutral)

Short: -0.53 (weak negative)

Signal:(42.484) Neutral

Seelos Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Seelos Therapeutics Inc Correlation - Currency/Commodity

-0.33
( neutral )

-0.50
( weak negative )

0.00
( neutral )

-0.45
( neutral )

Seelos Therapeutics Inc Financials

Annual	2023
Revenue:	$2.20M
Gross Profit:	$2.15M (97.41 %)
EPS:	$-7.73

Q4	2023
Revenue:	$653 000
Gross Profit:	$638 000 (97.70 %)
EPS:	$-0.560

Q3	2023
Revenue:	$406 000
Gross Profit:	$392 000 (96.55 %)
EPS:	$2.33

Q2	2023
Revenue:	$336 000
Gross Profit:	$322 000 (95.83 %)
EPS:	$-6.71

Financial Reports:

No articles found.

Seelos Therapeutics Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.